| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 7.2 | 5.6 |
| Gross profit | 2.8 | 2.1 |
| Profit before tax | 0.4 | -0.7 |
| Net income | -0.1 | -0.5 |
| EPS (diluted, $ a share) | $-0.01 | $-0.32 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +28.0% |
|---|---|
| Gross margin | 39.1% |
| Operating margin | 4.0% |
10-Q filed with the SEC, NASDAQ: SNOA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Sonoma Pharmaceuticals, Inc.: key numbers
- Share price
- $0.8802Close, Nov 16
- Market cap
- $4.46M
- Shares outstanding
- 5.06MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Sonoma Pharmaceuticals, Inc.
All →Sonoma Pharmaceuticals Other 8-K Filing
Sonoma Pharmaceuticals adopted a Section 382 Rights Agreement (poison pill) to protect its net operating loss carryforwards (NOLs) from being limited by an 'ownership change'. The agreement issues one preferred stock purchase right for each share of common stock, intended to deter any person or group from acquiring 5% or more of the company's shares.
- Counterparty
- Computershare Inc.
Sonoma Pharmaceuticals Shareholder Meeting
Sonoma Pharmaceuticals held its annual meeting of stockholders on September 16, 2026, where shareholders elected Jerry McLaughlin as a Class III director. Stockholders also approved executive compensation on an advisory basis and ratified the appointment of Frazier & Deeter, LLC as the company's independent accounting firm for the fiscal year ending March 31, 2027.